DOCKET NO.: ALZA-0142 PATENT

Application No.: 10/645,467

Office Action Dated: December 5, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:** 

1-34. (canceled)

35. (previously presented) A method for treating involuntary incontinence in the patient,

wherein the method comprises admitting orally into the patient a sustained release once-a-day

dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of

oxybutynin and its pharmaceutically acceptable salt, that is administered in a sustained rate to

provide in the plasma of the patient an oxybutynin/desethylmetabolite ratio of between about

0.36 to about 0.41 for treating involuntary incontinence in the patient.

36. (previously presented) A method for treating involuntary incontinence in a patient,

wherein the method comprises admitting orally into the patient a sustained release once-a-day

dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of

oxybutynin and its pharmaceutically acceptable salt, that is administered in a sustained rate to

provide in the plasma of the patient an oxybutynin/desethylmetabolite ratio greater than about

0.36 for treating involuntary incontinence in the patient.

37. (currently amended) The method according to any one of Claims 32, 33, 34, 35 or 36

Claim 35 or Claim 36 wherein the incidence of side effects associated with oxybutynin

treatment is reduced.

38-40. (canceled)

41. (previously presented) A method for managing the concentrations of oxybutynin

(OXY) and its desethylmetabolite (DESOXY) in the plasma of a patient, wherein the method

comprises admitting orally into the patient a once-a-day dosage form comprising 5 mg to 250

mg of a member selected from the group consisting of oxybutynin and its pharmaceutically

acceptable salt, that is administered at a controlled rate to provide an OXY/DESOXY ratio of

Page 2 of 5

**PATENT** 

**DOCKET NO.:** ALZA-0142 **Application No.:** 10/645,467

Office Action Dated: December 5, 2005

between about 0.36 to about 0.41 for managing the plasma concentrations and treating incontinence in the patient.

- 42. (previously presented) A method for managing the concentrations of oxybutynin (OXY) and its desethylmetabolite (DESOXY) in the plasma of a patient, wherein the method comprises admitting orally into the patient a once-a-day dosage form comprising 5 mg to 250 mg of a member from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that is administered at a controlled rate to provide an OXY/DESOXY ratio greater than about 0.36 for managing the plasma concentrations and treating incontinence in the patient.
- 43. (currently amended) The method according to any one of Claims 38, 39, 40, 41 or 42 Claim 41 or Claim 42 wherein the incidence of side effects associated with oxybutynin treatment is reduced.